Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Gritstone Oncology

Gritstone Oncology?uq=w9if130k
2015 FOUNDED
PRIVATE STATUS
41-50 EMPLOYEES
Series B LATEST DEAL TYPE
$92.7M LATEST DEAL AMOUNT
13 INVESTORS
Description

Operator of an immuno-oncology platform designed to develop next-generation personalized cancer therapeutics. The company's immuno-oncology platform develops personalized cancer therapy by exploiting the inherent vulnerability of cancer tumor cells as well as identifying patient's unique set of tumor antigens thereby using them in a therapeutic immunization strategy, enabling patients to recover faster from cancer.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Primary Office
  • 5858 Horton Street
  • Suite 210
  • Emeryville, CA 94608
  • United States

+1 (510) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Gritstone Oncology’s full profile, request a free trial.

Gritstone Oncology Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 07-Sep-2017 $92.7M 00000 00000 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 01-Apr-2016 000.00 000.00 000.00 Completed Pre-Clinical Trials
To view this company’s complete deal history including valuation and funding, request access »

Gritstone Oncology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 000
Series A 00,000,000 00.000000 00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

Gritstone Oncology Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Bay City Capital Venture Capital Minority 000 0000 000000 0
GV Corporate Venture Capital Minority 000 0000 000000 0
Lilly Asia Ventures Venture Capital Minority 000 0000 000000 0
Trinitas Capital (Beijing) Other Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

Gritstone Oncology Executive Team (14)

Name Title Board
Seat
Contact
Info
Jean-Marc Bellemin Chief Financial Officer & Executive Vice President, Finance
Roman Yelensky Ph.D Chief Technology Officer & Executive Vice President
Karin Jooss Ph.D Executive Vice President, Research & Chief Scientific Officer
Matthew Hawryluk Ph.D Executive Vice President & Chief Business Officer
Laura Veckerelli Executive
You’re viewing 5 of 14 executives. Get the full list »

Gritstone Oncology Board Members (6)

Name Representing Role Since Contact
Info
Judith Li Lilly Asia Ventures Board Member 000 0000
Nicholas Simon Clarus Ventures Board Member 000 0000
Patrick Mahaffy Self Chairman 000 0000
Peter Svennilson The Column Group Board Member 000 0000
Richard Heyman Ph.D Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »